UNC-Chapel Hill Coronavirus Research

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

A Partnership for Global Health: Expanding Curriculum and Research in Global Health at the University of North Carolina at Chapel Hill

Seroepidemiology and risk factors for SARS-CoV-2 infection among household members of food processing and farm workers in North Carolina

Can vaccine prioritization reduce disparities in COVID-19 burden for historically marginalized populations?

COVID-19 Outcomes Stratified by Control Status of Hypertension and Diabetes: Preliminary Findings From PCORnet, U.S

Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review